3 hours ago
6
Key Highlights
- Pascal Soriot, AstraZeneca’s Chief Executive, acquired 60,000 company shares valued at £121.02 per share on September 14, 2026
- European Medicines Agency’s CHMP delivered a favorable assessment for Klygefa (gefurulimab) targeting generalised myasthenia gravis
- The Phase III PREVAIL clinical study demonstrated Klygefa successfully achieved its primary efficacy measure, with findings featured in JAMA Neurology
- Pending final approval, Klygefa could become the European Union’s inaugural dual-binding nanobody C5 inhibitor for this specific indication
- Additional regulatory assessments for Klygefa are underway across the US, China, and multiple international territories
In a substantial demonstration of confidence, Pascal Soriot, Chief Executive of AstraZeneca, committed more than £7.26 million to acquire 60,000 ordinary shares of the pharmaceutical giant at a price of £121.02 per unit on September 14, 2026, through the London Stock Exchange. This transaction was formally reported in accordance with UK market abuse disclosure requirements.
This significant share acquisition occurred during the same timeframe that AstraZeneca’s specialized rare disease division, Alexion, secured an important regulatory milestone within European markets.
The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency delivered a favorable recommendation supporting the authorization of Klygefa (gefurulimab) throughout the European Union. The proposed indication covers use as adjunctive treatment for adults with generalised myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies.
Generalised myasthenia gravis represents a rare autoimmune condition characterized by debilitating muscle weakness and compromised muscular function. Within five major European nations—Germany, France, the United Kingdom, Italy, and Spain—approximately 82,500 individuals live with gMG, with roughly 66,000 classified as AChR-positive.
The favorable CHMP assessment drew upon data generated from the Phase III PREVAIL clinical investigation. Study outcomes were formally published in the peer-reviewed journal JAMA Neurology.
Klygefa successfully achieved its primary efficacy objective within the clinical trial. Results demonstrated a statistically meaningful improvement from baseline measurements using the Myasthenia Gravis Activities of Daily Living assessment at the 26-week mark compared with placebo. The treatment difference registered at -1.6, accompanied by a p-value below 0.0001.
Beneficial effects emerged as early as the first week of treatment and remained consistent throughout the entire 26-week study duration.
Groundbreaking Treatment Option
Should the European Commission grant formal authorization following the CHMP recommendation—which represents standard procedure—Klygefa would establish itself as the pioneering dual-binding nanobody C5 inhibitor sanctioned for this particular patient demographic within European Union territories.
The therapeutic agent requires weekly administration through subcutaneous self-injection utilizing an autoinjector device, offering patients a practical treatment option suitable for home administration.
Clinical data indicated Klygefa demonstrated favorable tolerability overall. The safety characteristics aligned with previous studies involving C5 inhibitor medications eculizumab and ravulizumab in generalised myasthenia gravis patient populations.
Global Regulatory Landscape
Klygefa has secured marketing authorization in Japan and various other nations for specific adult gMG patient populations.
Applications for regulatory approval drawing on PREVAIL study data remain under active evaluation by authorities in the United States and China, alongside other international jurisdictions.
AZN stock advanced 0.63% at the time of this report. Current analyst consensus maintains a Buy recommendation on AZN shares, establishing a price target of £15,200.
The pharmaceutical company maintains a market capitalization of £188.2 billion, accompanied by typical daily trading activity of approximately 3.3 million shares.
The post AstraZeneca (AZN) Stock Gains Momentum Following CEO Share Purchase and European Drug Approval appeared first on Blockonomi.
English (US) ·